AHMEDABAD: Solar Prescribed drugs on Wednesday posted a 5% rise in its consolidated web revenue which stood at Rs 2,375.5 crore for the second quarter of FY 2024. Within the year-ago interval, the corporate posted Rs 2,262.2 crore of revenue, Solar Pharma stated in a regulatory submitting.
The pharma main’s income stood at Rs 12,192 crore, up 11.3% from the year-ago interval whereas its earnings earlier than curiosity, taxes, depreciation, and amortization (EBITDA) got here in at Rs 3,179 crore.
Section-wise, Solar Pharma’s India formulation gross sales at Rs 3,842.5 crore, up 11.1% towards Q2 final 12 months. US formulation gross sales clocked in at $430 million, up 4.2% through the quarter.
Solar Pharma has six merchandise in its international specialty pipeline. This contains deuruxolitinib, presently filed with the US FDA for alopecia remedy and Nidlegy for pores and skin most cancers remedy.
Commenting on the outcomes, Dilip Shanghvi, Managing Director of the Firm stated, “US FDA’s acceptance of deuruxolitinib NDA for remedy of reasonable to extreme alopecia areata marks an vital milestone. There are restricted remedy choices for alopecia areata and deuruxolitinib ought to make a significant distinction in affected person lives, as soon as permitted. Equally, one other late stage candidate Nidlegy will doubtlessly complement our Odomzo franchise. Nidlegy’s current optimistic phase-3 information in sufferers with regionally superior totally resectable melanoma positions us to offer affected person options throughout a broad spectrum of pores and skin cancers.”
For Q2 FY24, exterior gross sales of API have been at Rs 497.2 crore, up by 5.1% over Q2 final 12 months. “Our API enterprise imparts advantages of vertical integration and continuity of provide chain for our formulations enterprise. We proceed to concentrate on growing API provide for captive consumption for key merchandise,” the corporate stated in a press release.
The pharma main’s income stood at Rs 12,192 crore, up 11.3% from the year-ago interval whereas its earnings earlier than curiosity, taxes, depreciation, and amortization (EBITDA) got here in at Rs 3,179 crore.
Section-wise, Solar Pharma’s India formulation gross sales at Rs 3,842.5 crore, up 11.1% towards Q2 final 12 months. US formulation gross sales clocked in at $430 million, up 4.2% through the quarter.
Solar Pharma has six merchandise in its international specialty pipeline. This contains deuruxolitinib, presently filed with the US FDA for alopecia remedy and Nidlegy for pores and skin most cancers remedy.
Commenting on the outcomes, Dilip Shanghvi, Managing Director of the Firm stated, “US FDA’s acceptance of deuruxolitinib NDA for remedy of reasonable to extreme alopecia areata marks an vital milestone. There are restricted remedy choices for alopecia areata and deuruxolitinib ought to make a significant distinction in affected person lives, as soon as permitted. Equally, one other late stage candidate Nidlegy will doubtlessly complement our Odomzo franchise. Nidlegy’s current optimistic phase-3 information in sufferers with regionally superior totally resectable melanoma positions us to offer affected person options throughout a broad spectrum of pores and skin cancers.”
For Q2 FY24, exterior gross sales of API have been at Rs 497.2 crore, up by 5.1% over Q2 final 12 months. “Our API enterprise imparts advantages of vertical integration and continuity of provide chain for our formulations enterprise. We proceed to concentrate on growing API provide for captive consumption for key merchandise,” the corporate stated in a press release.
